Lipid metabolism in MASLD and MASH: From mechanism to the clinicKeypoints
Summary: Metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD/MASH) is recognised as a metabolic disease characterised by excess intrahepatic lipid accumulation due to lipid overflow and synthesis, alongside impaired oxidation and/or export of these lipids. But where do th...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | JHEP Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589555924001897 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846148832019087360 |
|---|---|
| author | Fabrizia Carli Giuseppe Della Pepa Silvia Sabatini Antonio Vidal Puig Amalia Gastaldelli |
| author_facet | Fabrizia Carli Giuseppe Della Pepa Silvia Sabatini Antonio Vidal Puig Amalia Gastaldelli |
| author_sort | Fabrizia Carli |
| collection | DOAJ |
| description | Summary: Metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD/MASH) is recognised as a metabolic disease characterised by excess intrahepatic lipid accumulation due to lipid overflow and synthesis, alongside impaired oxidation and/or export of these lipids. But where do these lipids come from? The main pathways related to hepatic lipid accumulation are de novo lipogenesis and excess fatty acid transport to the liver (due to increased lipolysis, adipose tissue insulin resistance, as well as excess dietary fatty acid intake, in particular of saturated fatty acids). Not only triglycerides but also other lipids are secreted by the liver and are associated with a worse histological profile in MASH, as shown by lipidomics. Herein, we review the role of lipid metabolism in MASLD/MASH and discuss the impact of weight loss (diet, bariatric surgery, GLP-1RAs) or other pharmacological treatments (PPAR or THRβ agonists) on hepatic lipid metabolism, lipidomics, and the resolution of MASH. |
| format | Article |
| id | doaj-art-a743f822149e4466a57f080dd202ab1f |
| institution | Kabale University |
| issn | 2589-5559 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JHEP Reports |
| spelling | doaj-art-a743f822149e4466a57f080dd202ab1f2024-11-30T07:13:50ZengElsevierJHEP Reports2589-55592024-12-01612101185Lipid metabolism in MASLD and MASH: From mechanism to the clinicKeypointsFabrizia Carli0Giuseppe Della Pepa1Silvia Sabatini2Antonio Vidal Puig3Amalia Gastaldelli4Cardiometabolic Risk Laboratory, Institute of Clinical Physiology (IFC), National Research Council (CNR), Pisa, ItalyCardiometabolic Risk Laboratory, Institute of Clinical Physiology (IFC), National Research Council (CNR), Pisa, ItalyCardiometabolic Risk Laboratory, Institute of Clinical Physiology (IFC), National Research Council (CNR), Pisa, ItalyMetabolic Research Laboratories, Medical Research Council Institute of Metabolic Science University of Cambridge, Cambridge CB2 0QQ UK; Centro de Investigacion Principe Felipe Valencia 46012 Spain; Cambridge University Nanjing Centre of Technology and Innovation, Nanjing, ChinaCardiometabolic Risk Laboratory, Institute of Clinical Physiology (IFC), National Research Council (CNR), Pisa, Italy; Corresponding author. Address: Institute of Clinical Physiology, CNR, Via Giuseppe Moruzzi 1, 56124 Pisa Italy.Summary: Metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD/MASH) is recognised as a metabolic disease characterised by excess intrahepatic lipid accumulation due to lipid overflow and synthesis, alongside impaired oxidation and/or export of these lipids. But where do these lipids come from? The main pathways related to hepatic lipid accumulation are de novo lipogenesis and excess fatty acid transport to the liver (due to increased lipolysis, adipose tissue insulin resistance, as well as excess dietary fatty acid intake, in particular of saturated fatty acids). Not only triglycerides but also other lipids are secreted by the liver and are associated with a worse histological profile in MASH, as shown by lipidomics. Herein, we review the role of lipid metabolism in MASLD/MASH and discuss the impact of weight loss (diet, bariatric surgery, GLP-1RAs) or other pharmacological treatments (PPAR or THRβ agonists) on hepatic lipid metabolism, lipidomics, and the resolution of MASH.http://www.sciencedirect.com/science/article/pii/S2589555924001897Non-esterified fatty acidsde novo lipogenesismitochondrial functiondiet compositionhepatic lipid metabolism |
| spellingShingle | Fabrizia Carli Giuseppe Della Pepa Silvia Sabatini Antonio Vidal Puig Amalia Gastaldelli Lipid metabolism in MASLD and MASH: From mechanism to the clinicKeypoints JHEP Reports Non-esterified fatty acids de novo lipogenesis mitochondrial function diet composition hepatic lipid metabolism |
| title | Lipid metabolism in MASLD and MASH: From mechanism to the clinicKeypoints |
| title_full | Lipid metabolism in MASLD and MASH: From mechanism to the clinicKeypoints |
| title_fullStr | Lipid metabolism in MASLD and MASH: From mechanism to the clinicKeypoints |
| title_full_unstemmed | Lipid metabolism in MASLD and MASH: From mechanism to the clinicKeypoints |
| title_short | Lipid metabolism in MASLD and MASH: From mechanism to the clinicKeypoints |
| title_sort | lipid metabolism in masld and mash from mechanism to the clinickeypoints |
| topic | Non-esterified fatty acids de novo lipogenesis mitochondrial function diet composition hepatic lipid metabolism |
| url | http://www.sciencedirect.com/science/article/pii/S2589555924001897 |
| work_keys_str_mv | AT fabriziacarli lipidmetabolisminmasldandmashfrommechanismtotheclinickeypoints AT giuseppedellapepa lipidmetabolisminmasldandmashfrommechanismtotheclinickeypoints AT silviasabatini lipidmetabolisminmasldandmashfrommechanismtotheclinickeypoints AT antoniovidalpuig lipidmetabolisminmasldandmashfrommechanismtotheclinickeypoints AT amaliagastaldelli lipidmetabolisminmasldandmashfrommechanismtotheclinickeypoints |